Asymmetric dimethylarginine (ADMA) in EBC of asthmatic children Source: Annual Congress 2012 - Mechanisms and risk of childhood asthma and allergy Year: 2012
Asymmetric dimethylarginine (ADMA) to monitor treatments of pulmonary hypertension Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019
Asymmetric dimethylarginine and asthma Source: Eur Respir J 2014; 43: 647-648 Year: 2013
Asymmetric dimethylarginine, a biomarker for the effects of drug therapy in pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers Year: 2012
Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
Attenuated expression and activity of dimethylarginine dimethylaminohydrolase may play a key role in monocrotaline-induced pulmonary hypertension by accumulation of endogenous NOS inhibitors in rats Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006
Increased alveolar epithelial expression of dimethylarginine dimethylaminohydrolase 2 in idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 823s Year: 2006
The association between pulmonary arterial hypertension secondary to chronic lung disease and serum asymmetric dimethylarginine levels Source: Annual Congress 2012 - COPD comorbidities II Year: 2012
Asymmetric dimethylarginine (ADMA) in exhaled breath condensate (EBC) of children with cystic fibrosis (CF) Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015
Hypoxia induced pulmonary hypertension – the role of dimethylarginine dimethylaminohydrolase 1 (DDAH-1) in acute and sustained hypoxic vasoconstriction Source: Annual Congress 2009 - Pulmonary circulation Year: 2009
Plasma asymmetric dimethylarginine (ADMA) in pediatric patients with cystic fibrosis (CF) Source: International Congress 2016 – Systemic biomarkers Year: 2016
Biomarkers in pulmonary hypertension Source: Eur Respir J 2008; 32: 503-512 Year: 2008
NOS3 786C/T polymorphism associated with plasma nitric oxide level and risk of development essential hypertension in patients with asthma Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases Year: 2019
Heat shock proteins, L-arginine, and asymmetric dimethylarginine levels in patients with obstructive sleep apnea syndrome Source: International Congress 2015 – Inflammation, biomarkers and hypoxia in sleep disordered breathing Year: 2015
Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD Source: Eur Respir J, 51 (1) 1701457; 10.1183/13993003.01457-2017 Year: 2018
The role of inducible NO synthase (iNOS) in a cell model of steroid resistance in chronic obstructive pulmonary disease Source: Annual Congress 2008 - Basic science in asthma and COPD Year: 2008
Increased serum levels of IL-8 and TNFα in severe asthma compared to mild asthma: relationship with airway calibre and exhaled nitric oxide (FeNO) Source: Eur Respir J 2004; 24: Suppl. 48, 351s Year: 2004
Serum nitrotyrosine and nitric oxide levels in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 424s Year: 2002
Combination of elevated exhaled nitric oxide and serum eosinophil cationic protein identifies asthma patients at risk for exacerbation Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015
Increased nitric oxide synthase isoforms, endothelin 1 and apoptosis varied in lungs from patients with (SSc) and had impact on pulmonary function tests Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010